>ACROBiosystems’s speed on supporting Omicron variants research against COVID-19 pandemic
At the beginning of December, 2021, ACROBiosystems announced its new release of the whole set of coronavirus Omicron variant related proteins within 10 days. The high-quality controlled products will accelerate the speed of pharmaceutical research to tackle the COVID-19 pandemic.
“To support the research of new VOC variant Omicron of SARS-CoV-2, we immediately organized an emergency response team to develop related research tools, including antigens, antibodies, pseudoviruses and ELISA kits”, said Dr. Lili Qin, senior research and development manager of ACROBiosystems, “We have mobilized all forces to accelerate evaluation of this new emerging variant and the development of vaccines, neutralizing antibodies, antiviral drugs and detection reagents that target Omicron.”
At present, ACROBiosystems has successfully produced almost all core reagents for Omicron research and industrial production, including full-length Spike trimer of Omicron mutant that cover all 35 spike mutation sites, Spike RBD, S1, NTD, nucleocapsid protein. The purity of full-length Spike trimer is 96.8% as verified by SEC-MALS. Furthermore, the company has also successfully screened neutralizing antibodies from its antibody library, which can block Omicron spike-ACE2 interaction. A complete set of reagents available: Omicron antigens, neutralizing and binding antibody, pseufoviruses, ELISA kits, etc.
ACROBiosystems is a global leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. The company went public on Shenzhen stock market on October, 2021. ACROBiosystems aims to promote the rapid development of bio-pharmaceutical industry through products and business models innovation. The company has established long-term and stable partnership with the world top pharmaceutical enterprises, such as Pfizer, Novartis, and Johnson & Johnson, and well-known academic institutes.
The main products of ACROBiosystems are recombinant protein, services, kits, antibodies, and other related products. ACROBiosystems has very strict quality control system for its products, applied in biopharmaceutical research and development, production, and application. Its application includes target discovery and validation, candidate drug screening and optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.
Quick responding to COVID-19 pandemic, ACROBiosystems developed hundreds of products to facilitate the development of serologic tests, therapeutic antibodies, and vaccines. Lots of products have assisted customers receiving FDA emergency use authorization.
ACROBiosystems is determined to become a global cornerstone enterprise in the field of biomedical and health industry. Bringing value to customers by creating value for global pharmaceutical industry, through continuous developing new technologies, products, and actively empowering partners. ACROBiosystems is dedicated to accelerate the process of target therapeutic development, including target drugs and immunotherapeutic cytotherapy drugs, and to its better clinical application. Ultimately, making contributions to human health.
This web search service is supported by Google Inc.